Carvedilol in patients with risk factors for small for size syndrome following living donor liver transplantation (LDLT): A Prospective Multicentre Study
Ethical Clearance
Not Applied
Study Status
Not Yet Recruiting
Investigating Team
Dr. Dinesh Jothimani, Prof Mohamed Rela; Dr. Rela Institute and Medical Centre, Chennai
Study Design
•Study Design: Prospective, multicentre, open-label, 1:1 use of carvedilol 6.25 mg twice a day vs standard of care
Study Population: Adult LDLT recipients with high risk for SFSS within 72 hours of transplantation
•Methodology:
Eligible patients will receive oral carvedilol 6.25 mg twice daily, initiated within 72 hours of risk assessment.
Patients will be followed for 28 days and until 90 days post-initiation.
Primary Outcome
Prevention of development of SFSS
Secondary Outcome
- Changes in hepatic vascular inflow
- Graft function improvement
- Reduction in ICU/hospital stay
- Safety and tolerability of carvedilol